Your browser doesn't support javascript.
loading
A blueprint for the implementation of a validated approach for the detection of SARS-Cov2 in clinical samples in academic facilities
Sushmita Sridhar; Sally Forrest; Iain Kean; Jamie Young; Josefin Bartholdson Scott; Mailis Maes; Joana Pereira-Dias; Surendra Parmar; Matthew Routledge; Lucy Rivett; Gordon Dougan; Michael Weekes; Martin Curran; Ian G. Goodfellow; Stephen Baker.
Affiliation
  • Sushmita Sridhar; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
  • Sally Forrest; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
  • Iain Kean; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
  • Jamie Young; Academic department of Medical genetics
  • Josefin Bartholdson Scott; Cambridge Institute of Therapeutic Immunology & Infectious Disease
  • Mailis Maes; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
  • Joana Pereira-Dias; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
  • Surendra Parmar; Public Health England Diagnostic Laboratory, Addenbrookes Hospital, Cambridge, UK
  • Matthew Routledge; Infectious Diseases, Addenbrookes Hospital, Cambridge, UK
  • Lucy Rivett; Infectious Diseases, Addenbrookes Hospital, Cambridge, UK
  • Gordon Dougan; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
  • Michael Weekes; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
  • Martin Curran; Public Health England Diagnostic Laboratory, Addenbrookes Hospital, Cambridge, UK
  • Ian G. Goodfellow; University of Cambridge
  • Stephen Baker; Cambridge University
Preprint in English | bioRxiv | ID: ppbiorxiv-041319
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
The COVID-19 pandemic is expanding at an unprecedented rate. As a result, diagnostic services are stretched to their limit, and there is a clear need for the provision of additional diagnostic capacity. Academic laboratories, many of which are closed due to governmental lockdowns, may be in a position to support local screening capacity by adapting their current laboratory practices. Here, we describe the process of developing a SARS-Cov2 diagnostic workflow in a conventional academic Containment Level 2 (CL2) laboratory. Our outline includes simple SARS-Cov2 deactivation upon contact, the methods for a quantitative real-time reverse transcriptase PCR (qRT-PCR) detecting SARS-Cov2, a description of process establishment and validation, and some considerations for establishing a similar workflow elsewhere. This was achieved under challenging circumstances through the collaborative efforts of scientists, clinical staff, and diagnostic staff to mitigate to the ongoing crisis. Within 14 days, we created a validated COVID-19 diagnostics service for healthcare workers in our local hospital. The described methods are not exhaustive, but we hope may offer support to other academic groups aiming to set up something comparable in a short time frame.
License
cc_by
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Diagnostic study / Experimental_studies / Prognostic study / Rct Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Diagnostic study / Experimental_studies / Prognostic study / Rct Language: English Year: 2020 Document type: Preprint
...